5 completed, 1 active not recruiting, 1 enrolling by invitation, 1 unknown. 3 Phase 1, 3 Phase 2, 2 Not applicable, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 2, Enrolling by invitation 1 |
| Phase 2 | 3 | Completed 3 |
| Not applicable | 2 | Active not recruiting 1, Completed 1 |
| Phase 4 | 1 | Completed 1 |
Follow Erythromelalgia: new trials by email Literature Review of Erythromelalgia trials Research Report on Erythromelalgia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 1b Study of BHV-7000 in Participants With Inherited Erythromelalgia BHV-7000, Placebo - Familial Erythromelalgia | Phase 1 | Enrolling by invitation | Biohaven Therapeutics Ltd. | 5 | 2026-01-15 | 2026-04-08 |
| EASE (Efficacy of ATX01 Study in Erythromelalgia) Amitriptyline Hydrochloride, Placebo - Erythromelalgia | Phase 2 | Completed | AlgoTherapeutix | 14 | 2023-06-14 | 2024-04-18 |
| Spinal Cord Stimulation for Refractory Pain in Erythromelalgia Burst Spinal Cord Stimulation, Sham spinal cord stimulation - Erythromelalgia | Not applicable | Active not recruiting | St. Olavs Hospital | 6 | 2019-08-26 | 2026-08-17 |
| Vascular and Neurologic Exploration of Small Nervous Fiber by Sudoscanner and QST impedance measurement and pain evaluation - Erythermalgia | Not applicable | Completed | Fondation Hôpital Saint-Joseph | 33 | 2017-01-12 | 2019-04-25 |
| Carbamazapine for Inherited Erythromelalgia Patients With NaV1.7 Mutations Carbamazepine, Placebo - Erythromelalgia | Phase 4 | Completed | VA Connecticut Healthcare System | 2 | 2014-04-01 | 2017-06-06 |
| Painful Channelopathies Study Observation - Erythromelalgia, Pain Insensitivity, Congenital | Unknown | King's College London | 100 | 2012-02-01 | 2019-09-17 | |
| Phase 2a, Exploratory Study to Evaluate the Safety, Efficacy, Tolerability and Pharmacokinetics of XPF-002 in Patients With Primary/Inherited Erythromelalgia XPF-002, Placebo - Primary Erythromelalgia, Inherited Erythromelalgia | Phase 1 / Phase 2 | Completed | Xenon Pharmaceuticals Inc. | 8 | 2011-12-01 | 2014-04-14 |
| Study of XPF-001 in the Treatment of Pain From Primary/Inherited Erythromelalgia (IEM) XPF-001, Placebo - Primary Erythromelalgia, Inherited Erythromelalgia | Phase 1 / Phase 2 | Completed | Xenon Pharmaceuticals Inc. | 4 | 2010-04-01 | 2012-03-16 |
Cardiovascular Diseases (1) · Channelopathies (1) · Chronic Pain (1) · Generalized Epilepsy With Febrile Seizures Plus, 7 (1) · Hereditary Sensory and Autonomic Neuropathies (1) · Neuralgia (1) · Pain Insensitivity, Congenital (1) · Peripheral Vascular Diseases (1) · Vascular Diseases (1)
Cardiovascular Diseases (7) · Peripheral Vascular Diseases (7) · Vascular Diseases (7) · Nervous System Diseases (2) · Neurologic Manifestations (2) · Neuromuscular Diseases (2) · Pain (2) · Pathological Conditions, Signs and Symptoms (2) · Peripheral Nervous System Diseases (2) · Signs and Symptoms (2) · Congenital Abnormalities (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Genetic Diseases, Inborn (1) · Heredodegenerative Disorders, Nervous System (1) · Nervous System Malformations (1)
Amitriptyline (1) · Carbamazepine (1) · Observation (1)
Xenon Pharmaceuticals Inc. (2) · AlgoTherapeutix (1) · Biohaven Therapeutics Ltd. (1) · Fondation Hôpital Saint-Joseph (1) · King's College London (1) · St. Olavs Hospital (1) · VA Connecticut Healthcare System (1)
United States (4) · France (1) · Germany (1) · Netherlands (1) · Norway (1) · United Kingdom (1)
Almena L Free, MD (1) · Joost PH Drenth, MD PhD (1) · Sasha Gulati, md prof (1) · Stephen Waxman, MD, PhD (1)
2009 (1)